Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam Pharmaceuticals has entered a strategic collaboration with Inceptive Nucleics to leverage AI foundation models for the discovery of RNAi therapeutics. The deal is valued at up to $2 billion, including a $30 million upfront payment comprising cash and equity in Inceptive, with additional payments tied to preclinical, regulatory, and commercial milestones.
Key figures
- Deal Value Usd
- 2000000000
- Upfront payment
- 30000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.